Canntab Therapeutics Limited
CTABF
$0.00
$0.000.00%
OTC PK
| 02/28/2023 | 11/30/2022 | 08/31/2022 | 05/31/2022 | 02/28/2022 | |
|---|---|---|---|---|---|
| Net Income | 29.53% | 31.62% | 14.61% | 15.68% | -63.35% |
| Total Depreciation and Amortization | -14.72% | -16.89% | -17.72% | 19.52% | 57.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | 6.56% |
| Total Other Non-Cash Items | 19.26% | -52.85% | -19.66% | -76.84% | 25.73% |
| Change in Net Operating Assets | 161.29% | -26.72% | -788.37% | 70.88% | 86.01% |
| Cash from Operations | 55.24% | 21.47% | -5.52% | -2.30% | -13.33% |
| Capital Expenditure | 100.00% | 100.22% | 99.47% | 88.61% | 49.32% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 48.70% | -4.64% | 58.17% | 17.68% | 25.40% |
| Cash from Investing | -179.49% | 187.85% | 169.09% | 144.19% | 109.38% |
| Total Debt Issued | -100.00% | -12.86% | -12.86% | -12.86% | -2.06% |
| Total Debt Repaid | 7.91% | -33.09% | 15.12% | 18.70% | 8.47% |
| Issuance of Common Stock | -100.00% | -68.57% | -67.85% | -44.26% | -12.59% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -101.71% | -41.42% | -40.37% | -27.51% | 1.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3,041.48% | -207.41% | -1,128.04% | -56.44% | 219.82% |